Powered by

Novartis Kisqali(R) data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer

Dec 09, 2020 - Thomson Reuters ONE

- Findings presented at SABCS from largest intrinsic subtype analysis show Kisqali is unique among CDK4/6 inhibitors, delivers consistent efficacy across main HR+/HER2- intrinsic subtypes1

- Benefit seen even in patients with the endocrine-resistant HER2-enriched subtype, who face poor prognosis with endocrine therapy alone, reinforces Kisqali as first line treatment choice for all patients2

- Data presented at SABCS also show Kisqali more selectively inhibits CDK4, the active target...